Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
K73-03 is a synthetic small molecule derivative of oleanolic acid (OA) that functions as a potent inhibitor of the epidermal growth factor receptor (EGFR). Identified through reverse pharmacophore screening and molecular dynamics simulations, K73-03 has demonstrated significant antineoplastic activity against pancreatic cancer, specifically targeting the ASPC-1 cell line. Its mechanism of action involves blocking the EGFR/Akt signaling pathway, which leads to a reduction in the phosphorylation of EGFR and Akt. This inhibition triggers dose-dependent apoptosis and autophagy in cancer cells. Preclinical studies in xenograft models have shown that K73-03 effectively suppresses tumor growth, highlighting its potential as a targeted therapy for pancreatic cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on K73-03.